Hospital Medicine Unplugged

In this episode of Hospital Medicine Unplugged, we cut through ascending cholangitis—recognize fast, resuscitate early, hit bugs hard, drain the duct.
We open with the do-firsts: aggressive IV fluids, hemodynamic stabilization, early broad-spectrum antibiotics, and urgent source control planning. Loop in GI/advanced endoscopy, interventional radiology, surgery, and ICU from the start.
How to call it—diagnosis without delay: fever, RUQ pain, jaundice (Charcot’s triad) when present, plus labs of infection + cholestasis and imaging (US first; CT or MRCP if equivocal) showing ductal dilation/obstruction. Remember: the triad is insensitive—don’t wait for all three.
Stratify with Tokyo Guidelines because timing rides on severity:• Grade III (severe) = organ dysfunction → emergent biliary decompression + ICU care.• Grade II (moderate) = high fever, WBC extremes, age ≥75, Tbili ≥5, hypoalbuminemia, local inflammation → early drainage.• Grade I (mild) = start antibiotics + observe response; drain if no improvement.
Antibiotics—cover what’s common and what counts: Enterobacterales + Enterococcus, consider Pseudomonas/ESBL in healthcare-associated disease or prostheses. Typical choices: piperacillin–tazobactam for community-acquired without high-risk features; escalate to a carbapenem (± VRE coverage per local ecology) for severe/MDRO risk. Tailor to cultures. Duration is usually 3–5 days after source control.
Source control—the main event:• ERCP within 48–72 hours for most, and sooner for moderate/severe disease: sphincterotomy ± stone extraction, balloon sweep/basket, temporary stent if needed. Early ERCP links to lower mortality, less organ failure, shorter LOS.• If ERCP isn’t feasible: percutaneous transhepatic biliary drainage (PTBD), EUS-guided drainage, or surgical decompression—choose the fastest, safest route in your shop.• Malignant or complex strictures: prioritize decompression now (temporary stent), definitive oncologic work-up later.
ICU & adjuncts that matter: blood cultures before antibiotics (when it won’t delay therapy), correct coagulopathy, manage vasopressors judiciously, watch for AKI and post-ERCP pancreatitis. Reassess daily: vitals, mental status, bilirubin/ALP/AST/ALT, WBC/CRP, renal function, lactate. If fevers or labs stall, re-image and re-drain.
Pitfalls you can dodge:• Delaying drainage in Grade II/III.• Narrow empiric coverage too soon in stented/recurrent or healthcare-associated cases.• Missing atypical older/immunocompromised presentations (no fever/jaundice).• Skipping Enterococcus coverage where prostheses or prior ERCPs suggest it.
We close with the system moves—build a cholangitis bundle that: (1) screens with “fever + RUQ pain/jaundice or cholestasis” → STAT US (then CT/MRCP as needed); (2) gives antibiotics in triage; (3) auto-pages GI/IR/ICU for Grade II/III; (4) targets ERCP ≤48–72 h (sooner if severe) with a time-to-drainage KPI; (5) standardizes antibiotic narrowing to culture data; (6) bakes in post-ERCP monitoring and re-imaging triggers; (7) routes malignant/benign strictures to definitive follow-up after stabilization.
Bottom line: resuscitate, cover, and decompress—fast. Early ERCP changes outcomes; protocols make it reliable.

In this episode of Hospital Medicine Unplugged, we race through acute mesenteric ischemia (AMI)—recognize early, image fast, revascularize now, salvage bowel.
We open with the do-firsts: high-flow crystalloids, bowel rest + NG decompression, broad-spectrum antibiotics, and therapeutic anticoagulation (arterial/venous causes) unless contraindicated. Loop in surgery, vascular, interventional radiology, and ICU immediately.
Diagnosis that doesn’t dawdle:• Classic clue: severe abdominal pain out of proportion to exam; normal lactate/WBC do not exclude AMI.• Imaging: triphasic CT angiography is the gold standard—call it for sudden pain, high-risk hosts (AFib, atherosclerosis, shock, vasopressors, hypercoagulable states).• Use CTA to label the subtype: SMA embolus, in-situ arterial thrombosis, mesenteric venous thrombosis (MVT), or NOMI; assess perfusion and bowel viability.
Risk stratify (any = high risk): age >70, AFib or recent MI, diffuse atherosclerosis, shock/vasopressors, dialysis/cirrhosis/malignancy, hypercoagulable state, peritoneal signs, metabolic acidosis, CTA showing occlusion or non-enhancing bowel. High risk → parallel tracks (resuscitate + CTA + consults), not serial steps.
Definitive therapy—reperfuse early:• Arterial occlusion (embolus/thrombosis): endovascular-first (aspiration/lysis/thrombectomy ± angioplasty/stent) when feasible—lower mortality, less bowel resection, shorter LOS. Open surgery for peritonitis, failed endovascular, or instability; use damage-control with second-look 24–48h when viability’s unclear.• MVT: full-dose anticoagulation is first-line; operate only for peritonitis or failure of medical therapy.• NOMI: fix the physiology—optimize cardiac output, wean vasoconstrictors, correct hypovolemia; consider intra-arterial vasodilators (e.g., papaverine). Cut only if transmural necrosis/perforation.
Operative pearls when bowel’s threatened:• Resect frankly necrotic segments; preserve marginal bowel.• Second-look laparotomy reduces over-resection; plan it when any doubt remains.• Watch for reperfusion injury (acidosis, hyperK), compartment syndrome, and ongoing sepsis.
ICU & postoperative plays:• Serial exams + lactate/ABG/electrolytes, urine output, and hemodynamics.• Early enteral nutrition once perfusion is restored and bowel viable; TPN if needed after major resection.• Anticoagulation continuation (tailored to etiology and bleeding risk); evaluate for thrombophilia in idiopathic MVT.• Rehab and nutrition support to prevent short bowel syndrome.
What not to miss:• Delays kill—mortality often >50% without prompt diagnosis and revascularization.• Normal labs are false reassurance; do not wait for lactate to rise.• NOMI in the ICU is quiet—distension, diarrhea, or unexplained organ failure may be the only flags.• Overuse of vasopressors worsens splanchnic ischemia; prefer inotropes or vasodilator-friendly strategies when possible.
Medication and systems pitfalls:• Anticoagulation early improves survival and doesn’t meaningfully raise bleeding when monitored—don’t skip it without a reason.• Antibiotics up front for translocation risk; de-escalate when cultures guide.• Build the intestinal stroke pathway: (1) trigger = “pain out of proportion” or high-risk ICU decline → STAT CTA; (2) auto-page surgery + IR + ICU; (3) default endovascular-first for arterial occlusion; (4) algorithmic NOMI bundle (optimize flow, vasodilate, de-press); (5) mandatory second-look criteria; (6) standardized anticoag + nutrition protocols; (7) track time-to-CTA and time-to-reperfusion as quality metrics.
Take-home: Think AMI early, scan fast, anticoagulate, and revascularize—preferably endovascular—while you resuscitate. Treat the cause, spare the bowel, and standardize the system to drive down deaths and recurrences.

In this episode of Hospital Medicine Unplugged, we sprint through syncope—recognize the dangerous few, spare the benign many, and let the ECG lead the way.
We open with the do-firsts: define it right—transient LOC from global cerebral hypoperfusion with rapid, spontaneous recovery. Sort into the big three: cardiac, reflex/neurally mediated, and orthostatic. Cardiac etiologies drive morbidity/mortality—find them fast.
Initial evaluation that actually moves the needle: history (context, prodrome, exertion/supine, palpitations, meds), focused exam with orthostatic BPs, and a 12-lead ECG. These three steps often make the diagnosis and set the risk. Add targeted labs only when the story points (bleed, ischemia, electrolyte error).
Risk stratify with bedside red flags—abnormal ECG, known structural heart disease/HF, exertional or supine syncope, no prodrome, age ≥60, palpitations preceding LOC, family hx SCD, persistent hypotension, anemia/bleeding. Use a validated tool (e.g., Canadian Syncope Risk Score) to sharpen 30-day risk and disposition. Low risk? outpatient with education. High risk or unclear? admit/observe with telemetry.
In-hospital diagnostics—be precise, not profligate:• Telemetry for suspected cardiac syncope, abnormal ECG, or heart disease.• TTE for murmurs, HF signs, or structural suspicion.• Neuroimaging/EEG/CTPA/carotids only when the history/exam demands (focal deficits, head trauma, seizure concern, PE clues)—routine use has low yield.
Management—match therapy to mechanism:• Cardiac syncope: treat the cause—brady/tachy arrhythmias → pacing, ICD, ablation, antiarrhythmics; structural lesions (e.g., AS, HCM) → surgery/intervention; ischemia → ACS pathway. Early cardiology is key.• Reflex (vasovagal/situational/carotid sinus): education, hydration, salt, physical counterpressure; avoid triggers. For severe/recurrent: midodrine or fludrocortisone; pacing only for select cardioinhibitory phenotypes.• Orthostatic hypotension: de-prescribe culprits, replete volume, compression/abdominal binders, slow position changes; refractory cases → midodrine, fludrocortisone; treat underlying autonomic failure.
Observation & monitoring plays: structured protocols for intermediate-risk patients reduce unnecessary admissions, speed testing, and keep outcomes steady. Keep telemetry until an arrhythmic cause is excluded or a diagnosis lands.
Pitfalls you don’t want to meet:• Calling “syncope” with a prolonged post-ictal state—that’s seizure until proven otherwise.• Blanket ordering head CT, carotids, EEG, or CTPA without clinical signals.• Missing orthostatics or the med list (diuretics, vasodilators, QT-prolongers).• Stopping at “vasovagal” in an older adult with no prodrome and abnormal ECG.• Admitting every syncopal episode—risk tools + bedside clues safely steer many home.
Prognosis reality check: reflex and orthostatic—generally benign (recurrence > mortality). Cardiac syncope—highest short-term risk (arrhythmia, MI, SCD): act swiftly, treat definitively. Unexplained after work-up—risk tracks with age, cardiac history, and ECG.
We close with the system moves—a syncope bundle that (1) auto-captures orthostatic vitals and ECG in triage; (2) runs CSRS to gate observation vs. admission; (3) defaults to telemetry + TTE only when cardiac features present; (4) blocks routine neuro/PE testing without triggers; (5) standardizes reflex/orthostatic counseling + med optimization; (6) fast-tracks pacer/ICD/EP for arrhythmic pathways; (7) embeds clear return precautions and follow-up on discharge.
History + orthostatics + ECG, risk before tests, and mechanism-matched therapy—that’s how you turn a fall into a plan.

In this episode of Hospital Medicine Unplugged, we sprint through pulmonary hypertension (PH)—confirm the hemodynamics, protect the right ventricle, keep PAH therapy on, and don’t confuse Group 1 with the rest.
We open with the do-firsts: classify and hunt triggers. PH is mPAP >20 mm Hg; PAH (Group 1) adds PAWP ≤15 mm Hg and PVR ≥3 WU. Identify precipitants fast—infection, arrhythmia, volume shifts, med nonadherence—and correct them early. RV function drives outcomes.
Diagnostic snap: TTE for RV size/function and left-sided clues; ECG/CXR; targeted CT; V/Q scan for CTEPH; labs incl NT-proBNP. Right heart cath (RHC) when classification is unclear or before PAH-targeted therapy. Goal: pre- vs post-capillary split and reversible causes.
Risk stratify for admission to monitored/ICU care when: RV failure, hypotension/syncope, severe hypoxemia, rising lactate, escalating diuretic need, arrhythmia, perioperative context, or interruption of prostacyclin infusions.
Treatment—build the RV-protective backbone:• Oxygen to keep SpO₂ >92%; avoid hypoxia, hypercarbia, acidosis, pain/anxiety (they all raise PVR).• Preload optimization: gentle diuresis for congestion; avoid both dry RV and volume overload.• Maintain coronary perfusion: norepinephrine first-line vasopressor; vasopressin additive without ↑PVR.• Inotropes for low output: dobutamine or milrinone (watch BP).• Selective pulmonary vasodilation for decompensation: inhaled NO or inhaled prostacyclin; avoid systemic hypotension.• Ventilation: low tidal volume, cautious PEEP; prevent overdistension that spikes PVR.
PAH (Group 1) specifics—don’t miss the meds: Continue or promptly resume maintenance therapy (PDE-5i, ERAs, sGC stimulator, prostacyclin analogs). Never abruptly stop IV/SC prostacyclin—treat line issues like an emergency. Use combination therapy per risk; escalate (add prostacyclin or move to triple) if high-risk features persist after stabilization. Consider sotatercept as emerging add-on in select patients (specialist center).
Non–Group 1 PH: treat the cause• Group 2 (left heart): decongest, manage HF/valves; PAH drugs generally harm.• Group 3 (lung/hypoxia): optimize lung disease + O₂; consider inhaled treprostinil in select ILD-PH; avoid blanket PAH therapy.• Group 4 (CTEPH): lifelong anticoagulation; V/Q, refer early for endarterectomy or balloon pulmonary angioplasty; PAH drugs only if inoperable/residual.• Group 5: individualized.
Periop/ICU plays: meticulous lines for prostacyclin; bridging plans for procedures; avoid air emboli, sudden PEEP jumps, and systemic vasodilators without RV support. Multidisciplinary care with PH center involvement improves outcomes.
Monitoring that matters:• Telemetry, strict I/O, daily weights; trend NT-proBNP, creatinine, lactate, and mixed/central venous O₂ when available.• Echo for RV response if clinical course wobbles.• On heparins, use anti-Xa (not aPTT) if results are unreliable.
Pitfalls you don’t want to meet:• Starting PAH vasodilators before RHC when the phenotype is unclear.• Stopping prostacyclin for line swaps without overlap.• Flooding the RV in shock—pressors > fluid once congested.• High PEEP/overventilation → RV crash.• Treating Group 2/3 PH with PAH drugs by default.
We close with the system moves—a PH inpatient bundle that (1) flags RV failure early; (2) standardizes oxygen/diuresis/pressors/inotropes with RV-first targets; (3) auto-pages PH team for any prostacyclin patient or RHC-needed case; (4) locks in continuation of home PAH meds; (5) routes Group 4 to CTEPH workup; (6) embeds a ventilation/PEEP guardrail; (7) documents phenotype (pre vs post) before discharge with a clear escalation plan.
RV-centric, classification-driven, and therapy-continuous—stabilize the ventricle, treat the group, and never lose the line.

In this episode of Hospital Medicine Unplugged, we sprint through antiphospholipid syndrome (APS)—spot it early, anticoag fast, prevent recurrence, never miss CAPS.
We open with the do-firsts: assess for acute thrombosis (venous/arterial/microvascular), pregnancy history, triggers (infection, surgery, anticoagulant interruption), and extra-criteria clues (thrombocytopenia, livedo, valvular disease, neuro). Send aPL panel—LAC, aCL, anti-β2GPI—knowing diagnosis requires ≥1 clinical event + persistent antibody positivity ≥12 weeks. Flag high-risk phenotypes: triple-positive and coexisting SLE.
Call the diagnosis when the clinical picture (thrombosis and/or pregnancy morbidity) pairs with persistent aPL. Support with imaging (US/CTPA/brain MRI), TTE for valves/emboli, and exclude mimics (HIT, DIC, TTP, endocarditis, inherited thrombophilia).
Risk-stratify admission: new/worsening thrombosis, organ dysfunction, pregnancy, suspected CAPS, severe thrombocytopenia, or complex comorbidity. In-house: daily CBC/chemistry, INR/anti-Xa as appropriate, renal/hepatic checks, and watch for microangiopathy.
Treatment—build the anticoagulation backbone:• Acute VTE/arterial thrombosis: therapeutic UFH or LMWH → transition to warfarin (INR 2–3) for secondary prevention. Higher-intensity warfarin (INR 3–4) isn’t superior and bleeds more.• Arterial events (e.g., stroke): VKA (INR 2–3) generally preferred over antiplatelet alone; consider adding low-dose aspirin in select atherothrombotic profiles.• DOACs: avoid in high-risk APS (especially triple-positive) due to inferior efficacy; consider only in carefully selected low-risk scenarios when VKAs are truly not feasible.• Pregnancy: LMWH (prophylactic or therapeutic) + low-dose aspirin; add hydroxychloroquine when SLE is present. Avoid warfarin (teratogenic) except in rare late-gestation valve indications with specialist input.
If the backbone buckles (recurrent events despite therapeutic INR, intolerance, or special phenotypes):• Confirm adherence/drug interactions and time-in-therapeutic range; consider LMWH as alternative long-term.• For inflammatory/non-criteria disease: hydroxychloroquine; refractory selected cases: rituximab for hematologic/valvular/skin disease.• Complement-targeted therapy (e.g., eculizumab) in refractory CAPS or severe complement-driven phenotypes—case-by-case.
CAPS—don’t miss it: rapid ≤1 week multiorgan small-vessel thrombosis (≥3 organs), thrombocytopenia/MAHA, precipitated by infection/surgery or anticoagulant withdrawal. Action: start “triple therapy” now—heparin + high-dose IV steroids + plasma exchange or IVIG. Add eculizumab or rituximab in refractory cases. Manage in ICU; send biopsies/hemolysis labs; culture aggressively; monitor for DIC.
Monitoring & tapering that stick:• Warfarin: target INR 2–3; check frequently; manage interactions (antibiotics, diet, antiepileptics).• Heparins: prefer anti-Xa monitoring when LAC confounds aPTT, pregnancy, renal dysfunction, obesity, or CAPS.• Track platelets, renal/hepatic function; echo for valve disease; re-test aPL ≥12 weeks to document persistence (not to decide acute care).
Pitfalls you don’t want to meet:• Calling APS on a single positive test (transient aPL are common).• Using DOACs in triple-positive APS (↑ recurrence).• Under-anticoagulating arterial APS or stopping VKAs after an unprovoked event (indefinite therapy is usually indicated).• Misreading aPTT on heparin in LAC-positive patients—use anti-Xa.• Delaying CAPS therapy while waiting for labs.
Etiology plays (treat the cause/trigger):• Infection/surgery/estrogen exposure: remove/optimize; bridge perioperatively with LMWH; resume VKA promptly.• SLE: tight disease control; HCQ benefits thrombotic risk.• Pregnancy care: maternal-fetal medicine + hematology; plan delivery/neuraxial timing around LMWH.
We close with the system moves—an APS inpatient bundle that: (1) auto-orders LAC/aCL/anti-β2GPI with reflex repeat plan at 12 weeks; (2) defaults to UFH/LMWH → warfarin (INR 2–3); (3) hard-stops DOACs in triple-positive/high-risk; (4) flags CAPS triggers and fires a triple-therapy pathway; (5) embeds anti-Xa monitoring when LAC present; (6) routes pregnant/SLE patients to co-managed tracks with LMWH+ASA±HCQ; (7) builds discharge plans for indefinite anticoagulation, drug-interaction counseling, and follow-up aPL testing.
Fast recognition, heparin-first, VKA-anchored, steroid-sparing unless CAPS—treat triggers, protect pregnancies, and never miss catastrophic APS.

In this episode of Hospital Medicine Unplugged, we tackle cyclic vomiting syndrome (CVS) in the inpatient world—abort fast, hydrate smart, calm the gut–brain axis, and plan the relapse-proof discharge.
We open with the do-firsts: confirm the stereotyped episodes + symptom-free intervals (Rome IV vibe), rule out red flags (intracranial, obstruction, metabolic), grab labs (electrolytes, glucose, renal, LFTs, lipase) and start dextrose-containing IV fluids early. Keep the room dark, quiet, low-stimulus—sensory brakes matter.
Abortive therapy—hit hard, hit early (even mid-emesis): most adults need ≥2 agents.• Triptan + antiemetic core: sumatriptan (NS 20 mg or SC 6 mg) + ondansetron IV/SL; alternatives: promethazine or prochlorperazine (rectal/IV).• Sedation that soothes: promethazine, diphenhydramine, or benzodiazepine (e.g., lorazepam 1–2 mg IV)—the classic “abortive cocktail.”• Refractory rescue: droperidol/haloperidol (sedating antipsychotics) or IV fosaprepitant (NK1). Consider metoclopramide as an adjunct.
Supportive care that changes the trajectory:• IV dextrose (D5NS; pediatric D10 as needed) to reverse catabolic debt and fix electrolytes.• IV antiemetics on a q4–6h PRN schedule rather than drips and guesses.• Analgesia without opioids: IV ketorolac first-line; keep narcotics for last-resort cases—opioids can worsen nausea and outcomes.
Target the comorbid drivers: treat anxiety, depression, migraine, autonomic dysfunction—they modulate episodes and recovery. Reduce cannabis and opioid exposure; cessation improves response to prophylaxis.
Imaging & tests—once, not endlessly: one-time upper GI imaging or EGD if never evaluated or atypical; avoid repeat studies for retching-induced lesions (e.g., Mallory–Weiss). Brain imaging only with neuro red flags. Skip gastric emptying during flares.
Severe/refractory pathway:• Escalate to NK1 blockade (fosaprepitant IV) when standard antiemetics fail.• If prolonged poor intake → parenteral nutrition or higher glucose infusion rates.• Watch for metabolic decompensation (especially mitochondrial phenotypes) and transient hypertension (Sato subtype).
Discharge that prevents bounce-backs:• Start or up-titrate prophylaxis for moderate–severe CVS: amitriptyline (first-line TCA); alternatives topiramate, aprepitant, zonisamide, levetiracetam; consider CoQ10/riboflavin adjuncts.• Send a written CVS Action Plan: home abortives (sumatriptan NS/SC, ondansetron SL, promethazine PR), sedation strategy, fluid goals, and clear ED triggers.• Build follow-up with GI + behavioral health; screen for substance use, sleep issues, and migraine.• Educate on sleep regularity, trigger avoidance, stress reduction, and early prodrome dosing—that’s where wins happen.
Pitfalls you don’t want to meet:• Under-dosing or single-agent therapy—combination beats monotherapy.• Skipping dextrose (treat the energy deficit, not just the nausea).• Reflexive opioids for abdominal pain.• Over-testing every admission—treat the pattern.• Discharging without prophylaxis + action plan + follow-up.
We close with a ward-ready bundle that (1) initiates dextrose-IVs + electrolytes early, (2) delivers a combo abortive cocktail (triptan + antiemetic ± sedation), (3) defaults to ketorolac for pain, (4) escalates to NK1 for refractory cases, (5) treats psych/migraine/autonomic comorbids, and (6) locks in prophylaxis and a personalized action plan before discharge.
Bottom line: Start fast, combine smart, sedate judiciously, avoid opioids, hydrate with dextrose, and discharge with prophylaxis + a plan.

In this episode of Hospital Medicine Unplugged, we cut through appendicitis—risk-stratify early, choose surgery vs. antibiotics deliberately, and match therapy to CT and patient factors.
We open with the do-firsts: focused history/exam, labs (CBC, CRP), pregnancy test when relevant, urinalysis, and CT A/P (gold standard in adults) to confirm and stage—high-risk CT flags include appendicolith, mass effect/phlegmon, or diameter ≥13 mm. Layer in frailty and peri-op risk tools (e.g., NSQIP) to personalize decisions in older/comorbid patients.
Call the stage to steer care:• Uncomplicated = inflamed appendix without perforation/abscess/phlegmon.• Complicated = perforation, abscess, phlegmon, or diffuse peritonitis.
Operate when the risk is high or the belly declares itself: generalized peritonitis, complicated disease, or high-risk CT features. Laparoscopic appendectomy leads on lower SSI, shorter LOS, and faster recovery vs open. Give pre-op antibiotics for all; post-op antibiotics are not needed in uncomplicated cases with source control. Close the stump with endoclips/suture/staple/endoloop—choose based on anatomy and resources.
Antibiotics-first is real—when the CT says it’s safe. For uncomplicated cases without high-risk imaging, offer a nonoperative pathway:• Empiric broad-spectrum (e.g., piperacillin-tazobactam; or cephalosporin + metronidazole; carbapenem if risk factors). Transition to oral as the patient stabilizes.• Expect ~70% initial success in selected adults, with lower pain scores and faster return to work vs immediate surgery.• Crossover triggers: clinical deterioration or no improvement within 24–48 h → appendectomy.• Teach recurrence trade-offs and arrange close follow-up.
Shared decision-making is non-negotiable. For CT-confirmed uncomplicated disease, both appendectomy and antibiotics are acceptable. We walk through risks, benefits, recovery time, recurrence/late failure with antibiotics, and surgical complications—then align with patient values, life context, and risk tolerance.
Supportive care that matters: IV fluids, analgesia, antiemetics, early mobilization, diet advance as tolerated. Trend fever, pain, WBC/CRP, and reassess exam frequently. In complicated cases after source control, 3–5 days of antibiotics (short, culture-guided) usually suffice.
Controversies you’ll meet on call:• Timing of surgery: early vs. delayed in phlegmon/abscess—tailor to stability and source control options.• Interval appendectomy (8–12 wk) after contained perforation—consider selectively (age ≥40, neoplasm risk, recurrent symptoms).• Drains: not routine—balance occlusion/fistula risk vs. benefit; reserve for uncontrolled contamination or large abscess cavities.• Emerging endoscopic approaches (e.g., endoscopic retrograde appendiceal interventions): promising, still evolving.
Discharge & follow-up plays:• Uncomplicated lap appy → home within ~24 h if tolerating PO and pain is controlled.• Nonoperative patients → clear return precautions, short-interval clinic check, and a plan if symptoms recur.• Adults ≥40 y treated nonoperatively or with complicated disease → consider colonoscopy/interval imaging to exclude neoplasm.• Document antibiotics, durations, and allergy/renal adjustments.
Pitfalls you don’t want to meet:• Treating “uncomplicated” disease that actually hides an appendicolith or phlegmon—read the CT carefully.• Prolonging antibiotics without source control in complicated cases.• Skipping shared decision-making—patients value choice when outcomes are comparable.• Forgetting pregnancy testing and pelvic etiologies in reproductive-age patients.
We close with a ward-ready bundle that (1) defaults to CT-led staging, (2) auto-flags high-risk CT for surgery, (3) offers a structured antibiotics-first track for low-risk uncomplicated cases with 24–48 h checkpoints, (4) standardizes pre-op antibiotics and post-op stewardship, (5) embeds frailty/NSQIP to individualize care, and (6) builds follow-up and recurrence education into every discharge.
Bottom line: image early, risk-stratify precisely, and match the plan to the patient—laparoscopic appendectomy for high-risk or declared abdomens; antibiotics-first for selected uncomplicated cases with tight monitoring and honest talk about recurrence.

In this episode of Hospital Medicine Unplugged, we sprint through hypophosphatemia—spot it early, fix the shift, replenish smart, protect the diaphragm and heart.
We open with the essentials: phosphate <2.5 mg/dL (mild 2–2.5, moderate 1–1.9, severe <1). High-risk crowds: ICU, alcohol use disorder, refeeding, DKA treatment, post-op. Why we care: respiratory failure, myocardial dysfunction/arrhythmias, rhabdo/hemolysis, encephalopathy.
Mechanisms at a glance:• Redistribution (insulin, glucose loads, respiratory alkalosis, refeeding).• Low intake/absorption (malnutrition, vit D deficiency, binders/antacids).• Renal loss (PTH/FGF23, tubular injury, Mg deficiency, diuretics).ATP + 2,3-BPG drop → poor oxygen delivery, weak muscles, fragile RBCs.
Do-firsts in the hospital: check serum phosphate in at-risk patients (especially when starting nutrition), and always pair with Mg/K/Ca and renal function. Remember: serum phosphate may undercall total body deficit in acute illness—treat the patient.
When to treat: <2.0 mg/dL, symptomatic, or any high-risk scenario (vented, refeeding, rhabdo, hemolysis, cardiac dysfunction). Individualize by severity, symptoms, kidneys, and concomitant electrolyte issues.
How to replete—enteral first if mild–moderate and gut works:• Oral phosphate (typ. 30–80 mmol/day divided). Noninferior to IV for mild–moderate cases and cheaper/greener. Add diet (e.g., milk has ~35 mmol/L phosphorus).• Co-treat Mg/K so phosphate stays up.
When to go IV (severe <1, symptomatic, no enteral route, ventilatory failure, rhabdo/hemolysis):• Use weight + severity–based protocols (e.g., ~0.5 mmol/kg for severe; common totals 40–60+ mmol over several hours).• Rates ~10 mmol/h are widely used; faster strategies can be safe if renal function is preserved and baseline K+ <4—but monitor closely.• Choose K-phos vs Na-phos by potassium level and EKG.• Adjust for CKD, and avoid overcorrection.
Monitoring that matters:• Recheck phosphate (q4–8h during IV, at least daily otherwise) plus Ca/K/Mg, and creatinine.• Watch for hypocalcemia (Ca×P product), hyperkalemia (with K-phos), soft-tissue calcification risk in renal impairment.• In refeeding, start slow calories, give thiamine, and front-load electrolytes—then escalate feeds.
Special situations:• Refeeding → start low/advance slow, aggressive P/K/Mg and thiamine, daily labs.• DKA recovery → falling phosphate is expected with insulin; treat if <2 or symptomatic.• Ventilated patients → low phosphate = weaning failure; prioritize IV repletion.• Renal transplant/FGF23-high states → renal wasting; may need sustained supplementation.• Primary hyperPTH / hungry bone → prolonged deficits; replace Ca/Mg/Phos together.
Pitfalls you don’t want to meet: treating the number without the context, ignoring magnesium, pushing K-phos into hyperkalemia, routine high-dose IV in CKD, and forgetting that respiratory alkalosis can tank phosphate even when stores are low-normal.
We close with a ward-ready bundle that sticks: (1) screen high-risk patients when feeds/insulin start; (2) stratify by symptoms + level; (3) oral first when you can, IV for severe/symptomatic; (4) pick K- vs Na-phos wisely; (5) co-replete Mg/K, protect Ca; (6) tight monitoring (phos/Ca/K/Mg/Cr); (7) fix the driver (refeeding plan, alcohol care, ventilator alkalosis, PTH/FGF23 issues). Restore ATP, lift the diaphragm, steady the rhythm—safe repletion saves function.